GLPG2938

Research use only, not for human use.

GLPG2938 is a potent and selective antagonist of S1P2.

GLPG2938 is a potent and selective antagonist of S1P2.

GLPG2938 (0.5~5 μM; HPF cells) significantly prevents the S1P-mediated contraction at all tested concentrations.

GLPG2938 (1~10 mg/kg; p.o.) displays a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score.GLPG2938 shows good pharmacokinetics, with long half-life, low clearance, and good bioavailability in all species, especially in dogs. Animal Model:Male C57BL/6 mice Dosage:1~10 mg/kg Administration:P.o.Result:Displayed a marked protective effect at all dosed tested, resulting in statistically significant reduction of the Ashcroft score. ?

1-(2-Ethoxy-6-(trifluoromethyl)pyridin-4-yl)-3-((5-methyl-6-(1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl)pyridazin-3-yl)methyl)urea

GPCR/G Protein

S1P Receptor

S1P2

——

——

2130996-00-6

503.4

C20H19F6N7O2

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (198.65 mM)

CCOc1cc(NC(NCc2nnc(-c3cn(C)nc3C(F)(F)F)c(C)c2)=O)cc(C(F)(F)F)n1

——

(-20℃)

With Ice Pack

≥ 2 years